Company Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.
The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.
BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 23, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,401 |
| CEO | Alexander Hardy |
Contact Details
Address: 105 Digital Drive Novato, California 94949 United States | |
| Phone | (415) 506-6700 |
| Website | biomarin.com |
Stock Details
| Ticker Symbol | BMRN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001048477 |
| CUSIP Number | 09061G101 |
| ISIN Number | US09061G1013 |
| Employer ID | 68-0397820 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Hardy | President, Chief Executive Officer and Director |
| Brian R. Mueller | Chief Financial Officer and Executive Vice President |
| George Eric Davis | Executive Vice President, Chief Legal Officer, General Counsel and Secretary |
| Jeffrey Robert Ajer | Executive Vice President and Chief Commercial Officer |
| Dr. Henry J. Fuchs M.D., Ph.D. | President of Worldwide Research and Development |
| Erin Burkhart | Group Vice President and Chief Accounting Officer |
| Dr. C. Greg Guyer Ph.D. | Executive Vice President and Chief Technical Officer |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer and Senior Vice President of Research and Early Development |
| Traci McCarty | Group Vice President of Investor Relations |
| Humaira Serajuddin | Senior Vice President and Chief Marketing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 4, 2024 | 144 | Filing |
| May 31, 2024 | 144 | Filing |
| May 30, 2024 | 144 | Filing |
| May 30, 2024 | 144 | Filing |
| May 30, 2024 | 144 | Filing |
| May 29, 2024 | 144 | Filing |
| May 28, 2024 | 144 | Filing |
| May 24, 2024 | 8-K | Current Report |